Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
3.530
-0.030 (-0.84%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Adagene Employees
Adagene had 128 employees as of December 31, 2025. The number of employees decreased by 10 or -7.25% compared to the previous year.
Employees
128
Change (1Y)
-10
Growth (1Y)
-7.25%
Revenue / Employee
$59,929
Profits / Employee
-$137,574
Market Cap
233.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Voyager Therapeutics | 141 |
| Heron Therapeutics | 128 |
| Orchestra BioMed Holdings | 86 |
| Keros Therapeutics | 78 |
| Camp4 Therapeutics | 48 |
| Milestone Pharmaceuticals | 38 |
| Fennec Pharmaceuticals | 35 |
| Sol-Gel Technologies | 28 |
ADAG News
- 11 days ago - Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types - GlobeNewsWire
- 15 days ago - Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - GlobeNewsWire
- 27 days ago - Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - GlobeNewsWire
- 27 days ago - Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - GlobeNewsWire
- 27 days ago - Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response - GlobeNewsWire
- 27 days ago - Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - GlobeNewsWire
- 2 months ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire